文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

一线斯鲁利单抗联合化疗对比安慰剂联合化疗对广泛期小细胞肺癌患者生存的影响:ASTRUM-005随机临床试验

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

这项国际双盲3期随机临床试验在6个国家114个中心纳入585例既往未接受系统治疗的广泛期小细胞肺癌患者,按2:1随机接受斯鲁利单抗或安慰剂联合卡铂和依托泊苷。斯鲁利单抗组中位总生存期显著长于安慰剂组(15.4个月 vs 10.9个月;HR 0.63),中位无进展生存期也显著延长(5.7个月 vs 4.3个月;HR 0.48)。

要点

  • 斯鲁利单抗组中位总生存期15.4个月,安慰剂组10.9个月(HR 0.63,95%CI 0.49-0.82;P<.001)。
  • 斯鲁利单抗组中位无进展生存期5.7个月,安慰剂组4.3个月(HR 0.48,95%CI 0.38-0.59)。
  • ≥3级治疗相关不良事件在斯鲁利单抗组为129例(33.2%),安慰剂组为54例(27.6%)。

核心结论

  • 在既往未治疗的广泛期小细胞肺癌患者中,斯鲁利单抗联合化疗较单纯化疗显著改善总生存期,支持斯鲁利单抗联合化疗作为该人群的一线治疗。

研究设计与样本

  • 国际、双盲、3期随机临床试验(ASTRUM-005),于2019年9月12日至2021年4月27日在6个国家114个医院中心入组患者。
  • 筛查894例患者,随机585例既往未接受系统治疗的广泛期小细胞肺癌患者,按2:1随机接受斯鲁利单抗4.5 mg/kg(n=389)或安慰剂(n=196)静脉给药每3周一次。
  • 所有患者接受卡铂和依托泊苷静脉给药每3周一次,最多12周;随访至2021年10月22日。
  • 主要终点为总生存期(期中分析预设显著性阈值双侧P<.012);次要终点13项,包括无进展生存期和不良事件。
  • 585例随机患者平均年龄61.1岁(SD 8.67),女性104例(17.8%);246例(42.1%)完成试验,465例(79.5%)中止研究治疗;所有患者均接受研究治疗并纳入主要分析。

主要发现

  • 截至数据截止日2021年10月22日,中位随访时间12.3个月(范围0.2-24.8个月)。
  • 斯鲁利单抗组中位总生存期15.4个月(95%CI 13.3个月-不可评估),安慰剂组10.9个月(95%CI 10.0-14.3个月)(HR 0.63,95%CI 0.49-0.82;P<.001)。
  • 独立放射学审查委员会评估的中位无进展生存期在斯鲁利单抗组为5.7个月(95%CI 5.5-6.9个月),安慰剂组为4.3个月(95%CI 4.2-4.5个月)(HR 0.48,95%CI 0.38-0.59)。
  • ≥3级治疗相关不良事件在斯鲁利单抗组发生于129例患者(33.2%),在安慰剂组发生于54例患者(27.6%)。

临床怎么用

  • 作者认为,斯鲁利单抗联合化疗支持作为既往未治疗的广泛期小细胞肺癌患者的一线治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Programmed cell death ligand 1 inhibitors combined with chemotherapy has changed the approach to first-line treatment in patients with extensive-stage small cell lung cancer (SCLC). It remained unknown whether adding a programmed cell death 1 (PD-1) inhibitor to chemotherapy provided similar or better benefits in patients with extensive-stage SCLC, which would add evidence on the efficacy of checkpoint inhibitors in the treatment of extensive-stage SCLC. OBJECTIVE: To evaluate the efficacy and adverse event profile of the PD-1 inhibitor serplulimab plus chemotherapy compared with placebo plus chemotherapy as first-line treatment in patients with extensive-stage SCLC. DESIGN, SETTING, AND PARTICIPANTS: This international, double-blind, phase 3 randomized clinical trial (ASTRUM-005) enrolled patients at 114 hospital sites in 6 countries between September 12, 2019, and April 27, 2021. Of 894 patients who were screened, 585 with extensive-stage SCLC who had not previously received systemic therapy were randomized. Patients were followed up through October 22, 2021. INTERVENTIONS: Patients were randomized 2:1 to receive either 4.5 mg/kg of serplulimab (n = 389) or placebo (n = 196) intravenously every 3 weeks. All patients received intravenous carboplatin and etoposide every 3 weeks for up to 12 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival (prespecified significance threshold at the interim analysis, 2-sided P < .012). There were 13 secondary outcomes, including progression-free survival and adverse events. RESULTS: Among the 585 patients who were randomized (mean age, 61.1 [SD, 8.67] years; 104 [17.8%] women), 246 (42.1%) completed the trial and 465 (79.5%) discontinued study treatment. All patients received study treatment and were included in the primary analyses. As of the data cutoff (October 22, 2021) for this interim analysis, the median duration of follow-up was 12.3 months (range, 0.2-24.8 months). The median overall survival was significantly longer in the serplulimab group (15.4 months [95% CI, 13.3 months-not evaluable]) than in the placebo group (10.9 months [95% CI, 10.0-14.3 months]) (hazard ratio, 0.63 [95% CI, 0.49-0.82]; P < .001). The median progression-free survival (assessed by an independent radiology review committee) also was longer in the serplulimab group (5.7 months [95% CI, 5.5-6.9 months]) than in the placebo group (4.3 months [95% CI, 4.2-4.5 months]) (hazard ratio, 0.48 [95% CI, 0.38-0.59]). Treatment-related adverse events that were grade 3 or higher occurred in 129 patients (33.2%) in the serplulimab group and in 54 patients (27.6%) in the placebo group. CONCLUSIONS AND RELEVANCE: Among patients with previously untreated extensive-stage SCLC, serplulimab plus chemotherapy significantly improved overall survival compared with chemotherapy alone, supporting the use of serplulimab plus chemotherapy as the first-line treatment for this patient population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04063163.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Cheng Y, Han L, Wu L, et al. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. JAMA. 2022. PMID: 36166026. doi:10.1001/jama.2022.16464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。